SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-297146
Filing Date
2023-12-18
Accepted
2023-12-18 08:31:53
Documents
12
Period of Report
2023-12-18
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d623942d8k.htm   iXBRL 8-K 26903
  Complete submission text file 0001193125-23-297146.txt   153222

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA impl-20231218.xsd EX-101.SCH 2839
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE impl-20231218_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE impl-20231218_pre.xml EX-101.PRE 11700
6 EXTRACTED XBRL INSTANCE DOCUMENT d623942d8k_htm.xml XML 3523
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 231492310
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)